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Abstract 
Background: Only a few reports have assessed the effectiveness of endoscopic biliary drainage (EBD) in hepatocel‑
lular carcinoma (HCC) patients with obstructive jaundice and liver dysfunction.
Methods: This was a retrospective study based on the clinical databases from the Okayama University Hospital and 
10 affiliated hospitals. All patients received EBD for jaundice or liver dysfunction. The indication for EBD was aggrava‑
tion of jaundice or liver dysfunction with intrahepatic bile duct (IHBD) dilation. The technical and clinical success rate, 
complications, factors associated with clinical failure, and survival duration were evaluated.
Results: A total of 107 patients were enrolled in this study. Technical success was achieved in 105 of 107 patients 
(98.1%). Clinical success was achieved in 85 of 105 patients (81%). Complications related to endoscopic retrograde 
cholangiography (ERC) occurred in 3 (2.8%) patients. Child–Pugh class C (odds ratio 3.90, 95% confidence interval 
[CI] 1.47–10.4, p = 0.0046) was the only factor associated with clinical failure, irrespective of successful drainage. 
The median survival duration was significantly longer in patients with clinical success than in those without clinical 
success (5.0 months vs. 0.93 months; hazard ratio [HR] 3.2, 95% CI 1.87–5.37). HCC Stage I/II/III (HR 0.57, CI 0.34–0.95, 
p = 0.032), absence of portal thrombosis (HR 0.52, CI 0.32–0.85, p = 0.0099), and clinical success (HR 0.39, CI 0.21–0.70, 
p = 0.0018) were significant factors associated with a long survival.
Conclusions: EBD for obstructive jaundice and liver dysfunction in patients with HCC can be performed safely with 
a high technical success rate. Clinical success can improve the survival duration, even in patients expected to have a 
poor prognosis.
Trial registration: Retrospectively registered.
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Background
Hepatocellular carcinoma (HCC) is the most common 
cancer worldwide and the most frequent cause of death 
by cancer. With advances made in the HCC diagnosis 
and treatment techniques in recent years, the rates of an 
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early tumor diagnosis and long-term survival have been 
increasing [1–8].
Jaundice is encountered in 5%-44% of patients with 
HCC at the time of the initial diagnosis and frequently 
occurs during the later stages of disease [2]. Jaundice 
and liver dysfunction are usually caused by diffuse tumor 
infiltration into the liver parenchyma, tumor invasion, 
and/or progressive terminal liver failure resulting from 
advanced underlying cirrhosis. Obstructive jaundice 
caused by tumor invasion or hemobilia is rare in HCC, 
with an incidence of 0.5%-13% [4], and HCC treat-
ments, such as percutaneous tumor ablation (PTA), arte-
rial embolization, and radiation therapy, rarely cause 
obstructive jaundice [9]. However, it is closely connected 
with patients’ mortality as well as jaundice caused by 
liver dysfunction. Although endoscopic biliary drain-
age (EBD) is considered useful and effective in patients 
with obstructive jaundice due to other malignant dis-
eases such as bile duct cancer and pancreatic cancer, only 
a few studies have investigated the effectiveness of EBD 
in HCC patients with obstructive jaundice and liver dys-
function or obstructive cholangitis, and most of them 
have only included a small number of patients [3].
We carried out a retrospective analysis of the outcomes 
of EBD for obstructive jaundice or liver dysfunction with 
or without cholangitis caused by HCC in a large number 
of patients and clarified the factors associated with treat-
ment success and prognosis extension.
Methods
This retrospective study was based on the clinical data-
bases of the Okayama University Hospital and 10 affili-
ated hospitals. Data were extracted from the patients 
who underwent endoscopic stent placement for obstruc-
tive jaundice caused by HCC from April 2013 to October 
2018. Biliary strictures considered to be associated with 
therapy for HCC, such as PTA, trans-arterial emboliza-
tion, and radiation therapy, were omitted. Informed con-
sent was obtained via an opt-out option on the website. 
The Institutional Review Board of Okayama University 
approved this study.
Reference for endoscopic treatment
The indication for endoscopic stent placement was aggra-
vation of jaundice or liver dysfunction with intrahepatic 
bile duct (IHBD) dilation. Some patients had cholangi-
tis in addition to jaundice or liver dysfunction. Jaundice 
was defined as a serum total bilirubin concentration over 
3 mg/dl, and liver dysfunction was defined as hepatobil-
iary enzyme elevation compared to the baseline of each 
patient. IHBD dilatation was defined when an axial scan 
by computed tomography, magnetic resonance imaging, 
or ultrasound sonography showed the lumen of the intra-
hepatic bile duct to be more than 2 mm in diameter.
In accordance with Tokyo Guidelines 2018 [10], chol-
angitis was defined as the presence of leukocytosis, 
elevation of C-reactive protein (CRP), or a fever (temper-
ature ≥ 38 °C), in addition to the findings indicating chol-
estasis and/or the IHBD dilatation previously mentioned.
Endoscopic procedures
Endoscopic retrograde cholangiography (ERC) was 
performed using a duodenoscope (TJF260V, JF260V; 
Olympus Optical Co., Tokyo, Japan) in all cases. After 
confirming the biliary stricture caused by HCC with 
ERC, a plastic stent (PS) or endoscopic nasobiliary drain-
age (ENBD) tube was placed. The stent diameter (5–7 Fr) 
varied depending on the diameter of the bile duct. The 
number of PS or ENBD tubes was chosen according to 
the number of branches divided by the stricture. In cases 
with several divided branches, a maximum of three stents 
was placed into the major branches: left hepatic duct, 
anterior branch of the right hepatic duct, and posterior 
branch of the right hepatic duct. ENBD was sometimes 
used for initial drainage for patients with hemobilia due 
to bleeding of HCC. If ENBD was effective and hemo-
stasis was confirmed, the ENBD tube was replaced with 
a PS to avoid cholestasis with a clot, even in cases with-
out biliary stricture. Metallic stents were not used due to 
reports indicating that the survival rate was significantly 
extended in patients with HCC undergoing endoscopic 
biliary draining with PSs compared to those treated with 
metallic stents [7]. In cases in which endoscopic proce-
dures were deemed difficult, percutaneous transhepatic 
biliary drainage (PTBD) was employed. If clinical success 
could not be achieved despite successful stent placement, 
then the type of stent, e.g. straight type or Zimmon type, 
was changed, and/or the branch into which the PS was 
placed was changed. In most cases, endoscopic sphinc-
terotomy was not performed in order to maintain the 
function of the sphincter of Oddi. Endoscopic sphinc-
terotomy was performed when multiple stents were 
required.
If a blood clot was detected, it was extracted by a bas-
ket and balloon catheters. After clinical success was 
achieved, follow-up ERC and stent exchange were sched-
uled two to three months post-treatment. In the patient 
had a poor condition, stents were kept in place with-
out scheduled stent exchange until stent obstruction 
occurred.
Evaluations
The outcomes were evaluated on technical success, clini-
cal success, and survival duration. Technical success was 
defined as successful placement of a PS or ENBD tube in 
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the first session. Clinical success was defined as at least 
a 30% reduction of jaundice based on liver function test 
results after technical success. In cases with cholangitis, 
the resolution of the inflammatory symptoms and labora-
tory data, in addition to the resolution of cholestasis find-
ings, was defined as clinical success. Clinical failure was 
defined as an unsuccessful placement of a PS or an ENBD 
tube or no achievement of the clinical success previously 
mentioned, irrespective of the successful placement of 
the PS or ENBD tube. The survival duration was defined 
as the time from the endoscopic procedure to death.
Adverse events were evaluated according to the ASGE 
classification of Standards of Practice Committee [11]. 
Pancreatitis was defined as severe abdominal pain requir-
ing an analgesic and a more than three-fold increase in 
serum amylase levels.
Statistical analyses
Statistical analyses were performed using the JMP® 14 
software program (SAS Institute Inc., Cary, NC, USA). 
We used the chi-square test or Fisher’s test to compare 
proportions and the Mann–Whitney U-test to compare 
the median values. We performed a univariate analysis to 
assess the risk of treatment failure using the chi-squared 
test. The survival rate about clinical factors was evaluated 
with the Kaplan–Meier method and Cox proportional 
hazard model for the univariate analysis. To identify clin-
ical factors associated with a long survival, factors with 
p < 0.05 in the univariate analysis were analyzed using a 
multivariate Cox model. The threshold for significance 
was a value of p < 0.05.
Results
Patients characteristics
A total of 107 patients underwent EBD. Table  1 sum-
marizes the patient characteristics. The most common 
causes of HCC were hepatitis C (43%). Child–Pugh class 
B was seen in about half of all patients (47%). In over half 
of all patients, the clinical stage was stage IV, the Barce-
lona Clinic Liver Cancer (BCLC) classification was C and 
D, and no portal vein invasion was identified. Cholangitis 
was present in 43 of 106 patients (40%). Prior to EBD, the 
median serum total bilirubin level in all 107 patients was 
6.47 (0.5–31.5) mg/dl. Prior to EBD, the maximum IHBD 
diameter was 8.0 (3.0–23) mm.
Technical and clinical outcomes
Bile duct stricture was identified in 94 of 107 (88%) 
patients, and hemobilia was identified in 34 patients 
(32%) by ERC. Causes of biliary obstruction were 
tumor invasion or tumor compression by HCC or met-
astatic lymph-node in 94 patients and hemobilia in 13 
patients. Multiple PSs were placed in 32 patients (30%), 
including 2 in 26 patients, and 3 in 6 patients.
The patient flow diagram and success rates are shown 
in Fig. 1. Technical success was achieved in 105 of 107 
patients (98.1%) in the first session. The reason for 
technical failure in the remaining two patients was that 
the tip of the PS could not pass through the stricture 
due to the hard nature of the stricture. In these two 
patients without technical success, no biliary drain-
age was performed due to liver failure in one patient, 
whereas PTBD was performed in the other patient, but 
clinical success still could not be achieved because of 
liver failure.
In 84 of 105 patients, clinical success was achieved at 
the 1st session. Of the 21 patients without clinical suc-
cess, 18 instances were thought to be due to liver failure, 
so a second session was not performed in these patients. 
The second session was performed for the remaining 
3 patients. The stent was replaced in two patients and 
added in one, but clinical success was achieved only in 
one of the patients who underwent stent exchange. The 
clinical success rate in all patients, including those with 
and without cholangitis, was 81.0%, 90.2%, and 75%, 
respectively. An ENBD tube was successfully placed in 
seven patients. Clinical success was achieved in six of 
Table 1 Patient characteristics
HBV: hepatitis B virus, HCV: hepatitis C virus, non-BC: not hepatitis B and C virus, 
BCLC: Barcelona Clinic Liver Cancer, T-Bil: Total bilirubin,EBS: endoscopic biliary 
stent, IHBD: intrahepatic bile duct
Patients 107
Age (mean ± SD) 71.5 ± 10.1
Sex (%)
Male/female 76 (71)/31 (29)
Etiology (%)
HCV/HBV/non‑BC 46 (43)/24 (22)/17 (33)
Child–Pugh score (%)
5/6/7/8/9/10/11/12/13/14/15 15 (14)/9 (8)/19 (18)/15 (14)/17 
(16)/19 (18)/10 (9)/2 (2)/0 (0)/0 
(0)/1 (1)
Child–pugh score (%)
A/B/C 25 (23)/50 (47)/32 (30)
HCC stage (%)
I/II/III/IV 6 (6)/6 (6)/38 (35)/57 (53)
BCLC classification (%)
0/A/B/C/D 2 (2)/11 (10)/16 (15)/46 (43)/32 (30)
Grade of portal vein invasion
VP0/1/2/3/4 58 (55)/2 (2)/13 (12)/12 (11)/21 (20)
Cholangitis (%)
Present/absent 43 (40)/64 (60)
T‑bill before EBS (median, mg/dl) 6.47 (0.5–31.5)
 IHBD diameter (median, mm) 8.0 (3.0–2.3)
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the seven patients, and the ENBD tube was successfully 
replaced with a PS.
Recurrent biliary obstruction (RBO) occurred in 40 of 
85 patients (47%) with clinical success during the obser-
vation period (median 96.5 days [IQR 30.5–189.5]). The 
causes of RBO were debris in 19 (49%), hemobilia in 12 
(31%), tumor growth in 5 (13%), and others in 3 (7%).
HCC treatment was performed after endoscopic treat-
ment in 41 of 107 patients. The details of HCC treatment 
in these patients were trans-arterial therapy in 28 (68%), 
molecular-targeted drugs in 7 (17%), radiation therapy 
in 4 (10%) and operation in 2 (5%). Of the 41 patients 
undergoing HCC treatment, clinical success after endo-
scopic treatment was achieved in 39.
In 80 of the 107 patients, the survival duration after 
EBD and causes of death were assessed. The reasons for 
death were HCC progression in 48 patients (45%), liver 
failure in 22 (20%), cholangitis in 5 (5%), and other dis-
eases in 5 (5%).
Adverse events
Complications related to ERC procedures occurred in 3 
(2.8%) of the 107 patients. Hyperamylasemia occurred 
in two patients. Both patients with hyperamylasemia 
had no abdominal pain and improved with conservative 
treatment. No post-ERCP pancreatitis occurred. In one 
patient who underwent ENBD for hemobilia, the total 
bilirubin level decreased gradually. However, bleeding 
was out of control, and seven days after ENBD, abdomi-
nal pain was reported. The patient was diagnosed with 
gallbladder hemorrhaging and cholecystitis by computed 
tomography. Despite receiving intravenous antibiotics, 
he died eight days after ERCP.
Clinical success and the survival
Table  2 shows the relationship between patient charac-
teristics and clinical failure after successful EBD. The 
Child–Pugh class (odds ratio [OR] 4.66, 95% confidence 
interval [CI] 1.23–30.5, p = 0.021) and BCLC classifica-
tion C/D (OR 3.90, 95% CI 1.47–10.4, p = 0.0046) were 
factors shown to be associated with clinical failure, irre-
spective of successful drainage in a univariable analysis. 
In a multivariate analysis, only the Child–Pugh class (OR 
2.85, p = 0.047) was associated with clinical failure, irre-
spective of successful drainage.
The median survival duration was significantly longer 
in patients with clinical success than in those without 
success (5.0  months vs. 0.93  months; hazard ratio [HR] 
3.2, 95% CI 1.87–5.37) (Fig.  2). In patients with Child–
Pugh class C, the survival duration among those with 
clinical success was longer than among those with clini-
cal failure (2.8 months vs. 0.93 months, p = 0.0235).
Table 3 shows the relationship between clinical factors 
and the survival duration after EBD. The Child–Pugh 
class (OR 1.70, 95% CI 1.04–2.71, p = 0.035), stage (HR 
2.35, 95% CI 1.47–3.84, p = 0.0005), BCLC classification 
(HR 2.58, 95% CI 1.51–4.42, p = 0.0002), portal thrombo-
sis (HR 0.44, 95% CI 0.27–0.70, p = 0.0005), HCC treat-
ment after ERCP (HR 0.32, 95% CI 0.18–0.52, P < 0.0001), 
and clinical course (HR 3.2, 95% CI 1.87–5.37, P < 0.0001) 
were associated with the survival duration after EBD in 
a univariate analysis. The absence of portal thrombosis 
(HR 0.52, 95% CI 0.28–0.96, p = 0.038), HCC treatment 
after ERCP (HR 0.39, 95% CI 0.21–0.70, p = 0.0015), and 
clinical success (HR 0.39, 95% CI 0.21–0.70, p = 0.0018) 
were significant factors associated with a long survival 
in a multivariate analysis. In patients with tumor portal 
Fig. 1 Clinical success was achieved in 85 (81.0%) patients. Most patients who failed to achieve clinical success at the first session were suspected 
of having liver failure
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thrombosis and without HCC treatment after ERCP, the 
survival duration among those with clinical success was 
longer than among those with clinical failure (4.3 months 
vs. 1.0  months, P < 0.0001; 3.8  months vs. 0.73  months, 
p = 0.0005).
Furthermore, the median survival duration was sig-
nificantly longer in patients with HCC treatment after 
ERCP than in those without treatment (12  months 
vs. 2.8  months; HR 4.3, 95% CI 4.93–21.5) (Fig.  3). 
Among patients without HCC treatment after ERCP, 
the median survival duration was significantly longer in 
patients with clinical success than in those with clini-
cal failure (3.8 months vs. 0.73 months; HR 2.1, 95% CI 
2.8–5.7) (Fig. 3).
Table 2 Univariate and multivariate analysis of factors associated with clinical success
OR: Odds ratio, CI: Confidential interval, BCLC: Barcelona Clinic Liver Cancer, IHBD: intrahepatic bile duct
Success (n = 85) Failue (n = 22) Univariate Multivariate
OR 95% CI p Value OR p Value
Age (%) 0.48–3.15 0.67
  > 72 43 (81) 10 (19) 1
 ≧72 42 (78) 12 (22) 1.23
Sex (%) 0.15–1.55 0.21
 Male 58 (76) 18 (24) 1
 Female 27 (87) 4 (13) 0.478
History of radiation therapy (%) 0.21–2.23 0.52
 Present 21 (84) 4 (16) 1
 Absent 64 (78) 18 (22) 0.677
Child–pugh (%) 0.52–3.48 0.54 0.047
 A/B 65 (87) 10 (13) 1 1
 C 20 (63) 12 (37) 3.90 2.85
Stage (%) 0.16–1.15 0.086
 I/II/III 41 (82) 9 (18) 1
 IV/V 44 (77) 13 (23) 1.35
BCLC classification (%) 0.175
 0/A/B 27 (93) 2 (7) 1 0.73–5.77 0.16 1
 C/D 20 (26) 58 (74) 4.66 2.84
Portal thrombosis (%)
 Present 36 (75) 12 (25) 1 0.13–1.08
 Absent 49 (83) 10 (17) 0.43
Biliary structure (%)
 Present 76 (81) 18 (19) 1 0.39–3.00 0.83
 Absent 9 (69) 4 (31) 2.01
Cholangitis (%)
 Present 37 (75) 6 (14) 1
 Absent 48 (75) 16 (25) 2.06
Hemobilia (%)
 Present 29 (85) 5 (15) 1
 Absent 56 (77) 17 (23) 1.76
IHBD diameter (%)
 ≦8 mm 44 (73) 16 (27) 1
  > 8 mm 41 (87) 6 (13) 0.40
Number of stents (%)
 ≦1 60 (80) 15 (20) 1
  > 1 25 (78) 7 (22) 1.12
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Discussion
In this study, we showed that endoscopic biliary drainage 
for obstructive jaundice in patients with HCC could be 
performed safely with a high technical success rate. Fur-
thermore, clinical success improves the survival duration, 
even in patients with poor prognostic factors of HCC, 
such as Child–Pugh score C, stage IV disease, and tumor 
portal thrombosis.
The technical success rate of EBD was 98.7% in our 
study. Reported success rates are 92.1%-100% [2, 3, 7], so 
our result is not inferior to previously reported findings. 
In our study, two patients who failed to achieve techni-
cal success had hard strictures that a stent could not pass 
through. Both cases had a history of radiation therapy for 
HCC. We believe that a hard stricture due to radiation 
therapy is associated with a risk of treatment failure.
The clinical success rate was 83% in our study. Reported 
success rates are 35.7%-75.9% [2, 3, 12–15], so our result 
is superior to that previously reported. The presence of 
IHBD dilatation is significantly associated with clinical 
Fig. 2 Patients with clinical success had a longer survival than those 
without clinical success (5.0 months vs. 0.93 months; HR 3.2, 95% CI 
1.87–5.37)
Table 3 Univariate and  multivariate analysis of  clinical factors associated with  survival time after  endoscopic biliary 
drainage
HR Univariate Multivariate
95% CI p value HR 95% CI p value
Median age (years) ≦72 1
 > 72 0.83 0.53–1.30 0.42
Sex Male 1
Female 0.87 0.52–1.42 0.59
History of radiation therapy Present 1
Absent 1.02 0.62–1.76 0.95
Child–Pugh A/B 1 1
C 1.7 1.04–2.71 0.035 1.17 0.64–2.13 0.62
Stage I/II/III 1 1
IV 2.35 1.47–3.84 0.0005 1.53 0.82–2.84 0.18
BCLC classification 0/A/B 1 1
C/D 2.58 1.51–4.42 0.0002 1.02 0.40–2.59 0.97
Portal thrombosis Present 1 1
Absent 0.44 0.27–0.70 0.0005 0.52 0.28–0.96 0.038
Biliary stricture Present 1
Absent 0.68 0.30–1.33 0.28
Cholangitis Present 1
Absent 0.82 0.53–1.30 0.41
Hemobilia Present 1
Absent 1.48 0.92–2.44 0.11
Plastic stent Single 1
Multiple 0.71 0.41–1.17 0.18
HCC treatment after ERCP Absent 1 1
Present 0.32 0.18–0.52  < 0.0001 0.39 0.21–0.70 0.0015
Clinical course Success 1 1
Failure 3.2 1.87–5.37  < 0.0001 2.59 1.42–4.71 0.0018
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success [3]. However, in our study, an inclusion criterion 
was the presence of IHBD dilation. Jaundice and liver 
dysfunction without IHBD dilatation in HCC patients 
are thought to indicate liver failure, which is difficult to 
improve via biliary drainage; this may explain why our 
findings were superior to those of previous studies. How-
ever, the clinical success rates of EBD in other malignant 
strictures, such as hilar cholangiocarcinoma, have been 
reported to range from 54% to 91.3% [16–19]. Our data 
are not inferior to those of previous reports on other 
malignant strictures, either.
Total complication rates reportedly range from 0% to 
21.7% [2, 7] in HCC stricture, and 5.3% to 47.8% [19] in 
other malignant strictures. The complication rate was 
2.8% in the present study (hyperamylasemia in 2, gall 
bladder hemorrhaging in 1), which was similar to the 
rates in other studies. The rate of post-ERCP pancreati-
tis (PEP) was reported to be 18.6% [3] for cases of HCC 
stricture and 0%-38.4% [19, 20] for cases of other malig-
nant stricture. Adler et  al. reported that patients with 
Child–Pugh class C had a higher risk of PEP than others 
[21]. However, whether or not the risk of PEP in patients 
with liver cirrhosis is high is controversial [22, 23]. In our 
study, although there were no cases of post-ERCP pan-
creatitis, the number of patients was small, so a larger 
prospective trial is required to resolve this issue.
In our study, Child–Pugh class C was significantly asso-
ciated with clinical failure. The clinical success rate was 
86.7% in cases of class A/B but only 62.5% in class C. In 
a previous report, the 1-year cumulative survival rates 
were 45% (Child C), 80% (Child B) and 95% (Child A). 
Patients with Child–Pugh class C have a poor prognosis 
because of liver failure [1, 24], so biliary drainage tends 
to be less effective in these patients than in others. How-
ever, on comparing the survival rates between the clini-
cal success and clinical failure cases among patients with 
Child–Pugh class C, the survival duration in the clinical 
success cases was longer than that in the clinical failure 
cases (2.8  months vs. 0.93  months, p = 0.0235). In our 
study, HCC treatment after ERCP was significantly asso-
ciated with a long survival. In addition, among patients 
without HCC treatment after ERCP, the median survival 
duration was significantly longer in patients with clinical 
success than in those with clinical failure. HCC treatment 
after ERCP is sometimes difficult in patients who can-
not achieve clinical success through endoscopic therapy. 
Therefore, clinical success with endoscopic therapy is 
thought to contribute to a long prognosis, both indirectly 
and directly.
Previous studies have shown that, in addition to suc-
cessful drainage, subsequent treatment for HCC, the 
liver function, and HCC tumor stage were significant 
factors associated with a long survival [2, 3, 8]. Our 
study found that portal thrombosis and clinical suc-
cess of ERCP were significant factors influencing the 
survival according to the multivariate analysis. Indeed, 
the survival duration in patients with clinical success 
was significantly longer than in those without clinical 
Fig. 3 The median survival duration was significantly longer in patients with HCC treatment after ERCP than in those without treatment (12 months 
vs. 2.8 months; HR 4.3, 95% CI 4.93–21.5). Among patients without HCC treatment after ERCP, the median survival duration was significantly longer 
in patients with clinical success than in those with clinical failure (3.8 months vs. 0.73 months; HR 2.1, 95% CI 2.8–5.7)
Page 8 of 9Matsumi et al. BMC Gastroenterol           (2021) 21:28 
success (HR 0.39, 95% CI 0.21–0.70, p = 0.0018). Suc-
cessful drainage may provide HCC patients with jaun-
dice an opportunity for an extended survival, not only 
through successful drainage itself but also through the 
opportunity to receive additional HCC treatment. Fur-
thermore, in patients with portal thrombosis who had 
a poor prognosis, when clinical success was achieved, 
their survival was extended (HR 0.23, 95% CI 0.11–
0.51, p = 0.0005).
Several limitations associated with the present study 
warrant mention. First, all data was reviewed retrospec-
tively. However, this was a multi-center trial, and the 
number of patients was over 100. To our knowledge, 
this report included the largest number of patients to 
date. Second, no data could be analyzed between the 
survival of the patients with successful biliary drainage 
in this study and that of the HCC patients without bil-
iary obstruction. Such data would reveal more clearly 
the effectiveness of biliary drainage in the patients with 
biliary obstruction with HCC. Third, we used only PSs 
for biliary drainage. A previous report mentioned that 
the survival rate was significantly longer in the PS group 
than in the metallic stent group when patients with HCC 
underwent endoscopic biliary drainage [7]. Therefore, 
we used PSs for biliary drainage in this study. However, 
no study has prospectively compared the effectiveness of 
biliary drainage using PSs with that using metallic stents 
in a large number of patients. Randomized controlled tri-
als in large cohorts are required to further investigate this 
issue. Finally, there may have been some selection bias in 
our study. When we decided whether or not to perform 
ERCP for HCC patients, we might have unknowingly 
excluded patients with a poor condition.
In conclusion, Child–Pugh class C is an important pre-
dictor of the effectiveness of endoscopic biliary drainage 
in HCC patients with liver dysfunction with or without 
cholangitis. When clinical success is achieved, the prog-
nosis is improved; therefore, we should actively promote 
biliary drainage for HCC jaundice.
Conclusions
EBD for obstructive jaundice and liver dysfunction in 
patients with HCC can be performed safely with a high 
technical success rate. Clinical success may extend the 
survival duration, even in patients expected to have a 
poor prognosis.
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